A Randomized Controlled Trial of Levetiracetam Compared with Phenobarbital in the Treatment of Neonatal Seizures

2019 ◽  
Author(s):  
Cynthia Sharpe ◽  
Gail E. Reiner ◽  
Suzanne L. Davis ◽  
Mark Nespeca ◽  
Jeffrey J. Gold ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Neonatal Seizures ◽  
Randomized Controlled

Effect of early withdrawal of phenobarbitone on the recurrence of neonatal seizures: An open-label randomized controlled trial

2021 ◽  
Vol 117 ◽  
pp. 107875
Author(s):  
Ankush Jindal ◽  
Suresh Kumar Angurana ◽  
Renu Suthar ◽  
Praveen Kumar ◽  
Venkataseshan Sundaram
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Neonatal Seizures ◽  
Open Label ◽  
Early Withdrawal ◽  
Randomized Controlled

Phenobarbitone versus phenytoin for treatment of neonatal seizures: An open-label randomized controlled trial

2013 ◽  
Vol 50 (8) ◽  
pp. 753-757 ◽  
Author(s):  
Garima Pathak ◽  
Amit Upadhyay ◽  
Umesh Pathak ◽  
Deepak Chawla ◽  
Sneh P. Goel
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Neonatal Seizures ◽  
Open Label ◽  
Randomized Controlled

scholarly journals Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial

PEDIATRICS ◽  
2020 ◽  
Vol 145 (6) ◽  
pp. e20193182 ◽  
Author(s):  
Cynthia Sharpe ◽  
Gail E. Reiner ◽  
Suzanne L. Davis ◽  
Mark Nespeca ◽  
Jeffrey J. Gold ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Neonatal Seizures ◽  
Randomized Controlled

scholarly journals Levetiracetam versus Phenobarbitone in Neonatal Seizures — A Randomized Controlled Trial

2019 ◽  
Vol 56 (8) ◽  
pp. 643-646 ◽  
Author(s):  
Vykuntaraju K. Gowda ◽  
Ayesha Romana ◽  
Niranjan H. Shivanna ◽  
Naveen Benakappa ◽  
Asha Benakappa
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Neonatal Seizures ◽  
Randomized Controlled

Effect of Treatment of Subclinical Neonatal Seizures Detected With aEEG: Randomized, Controlled Trial

PEDIATRICS ◽  
2010 ◽  
Vol 125 (2) ◽  
pp. e358-e366 ◽  
Author(s):  
L. G. M. van Rooij ◽  
M. C. Toet ◽  
A. C. van Huffelen ◽  
F. Groenendaal ◽  
W. Laan ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Neonatal Seizures ◽  
Randomized Controlled ◽  
Effect Of Treatment

scholarly journals Phenobarbitone versus levetiracetam in neonatal seizures

2020 ◽  
Vol 7 (8) ◽  
pp. 1701
Author(s):  
Ravindra Kumar Jain ◽  
Hemant Kumar
Keyword(s):  
Adverse Effect ◽  
Randomized Controlled Trial ◽  
Side Effects ◽  
Controlled Trial ◽  
Good Alternative ◽  
Preterm Neonates ◽  
Neonatal Seizures ◽  
Medical College ◽  
Randomized Controlled ◽  
To Receive

Background: There is increasing evidence that neonatal seizures have an adverse effect on neurodevelopmental progression and it may predispose to cognitive, behavioral or epileptic complications later in life. The objective of this study was to compare the efficacy of phenobarbitone and levetiracetam for the treatment of neonatal seizures in term and late preterm neonates. The study was aimed to know the efficacy of phenobarbitone (PB) in comparison with levetiracetam (LEV) in controlling neonatal seizures.Methods: This was a randomized controlled trial where data of the babies with seizures weighing more than 2 kg who were admitted in NICU of Muzaffarnagar Medical College was collected and analysed for intervention to either phenobarbitone or levetiracetam.Results: Clinically apparent seizures were controlled in only 65.38% neonates assigned to receive levetiracetam as compared to 76.92% neonates assigned to receive phenobarbitone.Conclusions: LEV although lesser effective than PB with very fewer side effects is found to be a good alternative in controlling neonatal seizures.

Treatment Fidelity Procedures for an Aphasia Intervention Within a Randomized Controlled Trial: Design, Feasibility, and Results

2020 ◽  
Vol 29 (1S) ◽  
pp. 412-424
Author(s):  
Elissa L. Conlon ◽  
Emily J. Braun ◽  
Edna M. Babbitt ◽  
Leora R. Cherney
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Treatment Protocol ◽  
Treatment Fidelity ◽  
Protocol Adherence ◽  
Study Condition ◽  
Randomized Controlled ◽  
Aphasia Therapy ◽  
Percent Accuracy ◽  
Over Time

Purpose This study reports on the treatment fidelity procedures implemented during a 5-year randomized controlled trial comparing intensive and distributed comprehensive aphasia therapy. Specifically, the results of 1 treatment, verb network strengthening treatment (VNeST), are examined. Method Eight participants were recruited for each of 7 consecutive cohorts for a total of 56 participants. Participants completed 60 hr of aphasia therapy, including 15 hr of VNeST. Two experienced speech-language pathologists delivered the treatment. To promote treatment fidelity, the study team developed a detailed manual of procedures and fidelity checklists, completed role plays to standardize treatment administration, and video-recorded all treatment sessions for review. To assess protocol adherence during treatment delivery, trained research assistants not involved in the treatment reviewed video recordings of a subset of randomly selected VNeST treatment sessions and completed the fidelity checklists. This process was completed for 32 participants representing 2 early cohorts and 2 later cohorts, which allowed for measurement of protocol adherence over time. Percent accuracy of protocol adherence was calculated across clinicians, cohorts, and study condition (intensive vs. distributed therapy). Results The fidelity procedures were sufficient to promote and verify a high level of adherence to the treatment protocol across clinicians, cohorts, and study condition. Conclusion Treatment fidelity strategies and monitoring are feasible when incorporated into the study design. Treatment fidelity monitoring should be completed at regular intervals during the course of a study to ensure that high levels of protocol adherence are maintained over time and across conditions.

Sign in / Sign up

Export Citation Format

Share Document